Description
LY-2183240 (874902-19-9) is highly potent inhibitor of cellular anandamide uptake (IC50 = 0.27nM1, 15nM2). LY-2183240 has also been found2-4 to be an inhibitor of fatty acid amide hydrolase (FAAH) – IC50 = 14nM4, diacylglycerol lipase (DAGL) and monoacylglycerol lipase (MAGL) – IC50 = 5.3 nM3.
Biological Activity
Novel and highly potent blocker of anandamide uptake (IC 50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC 50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.
References
[1] S A MOORE. Identification of a high-affinity binding site involved in the transport of endocannabinoids.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 49: 17852-17857. DOI:
10.1073/pnas.0507470102[2] GIORGIO ORTAR . Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation[J]. European Journal of Medicinal Chemistry, 2008, 43 1: Pages 62-72. DOI:
10.1016/j.ejmech.2007.02.023[3] JESSICA P. ALEXANDER Benjamin F C. The Putative Endocannabinoid Transport Blocker LY2183240 Is a Potent Inhibitor of FAAH and Several Other Brain Serine Hydrolases[J]. Journal of the American Chemical Society, 2006, 128 30: 9699-9704. DOI:
10.1021/ja062999h[4] AMY K DICKASON-CHESTERFIELD. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.[J]. Cellular and Molecular Neurobiology, 2006, 26 4-6: 407-423. DOI:
10.1007/s10571-006-9072-6